Related Experiment Video
Updated: Sep 20, 2025

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
Drug repurposing to identify potential FDA-approved drugs targeting three main angiogenesis receptors through a deep
Mohammadreza Torabi1, Soroush Sardari2, Alejandro Rodríguez-Martínez3
1Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Abstract:
Tumor cell survival depends on the presence of oxygen and nutrients provided by existing blood vessels, particularly when cancer is in its early stage. Along with tumor growth in the vicinity of blood vessels, malignant cells require more nutrients; hence, capillary sprouting occurs from parental vessels, a process known as angiogenesis. Although multiple cellular pathways have been identified, controlling them with one single biomolecule as a multi-target inhibitor could be an attractive strategy for reducing medication side effects. Three critical pathways in angiogenesis have been identified, which are activated by the vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), and epidermal growth factor receptor (EGFR). This study aimed to develop a methodology to discover multi-target inhibitors among over 2000 FDA-approved drugs. Hence, a novel ensemble approach was employed, comprising classification and regression models. First, three different deep autoencoder classifications were generated for each target individually. The top 100 trained models were selected for the high-throughput virtual screening step. After that, all identified molecules with a probability of more than 0.9 in more than 70% of the models were removed to ensure accurate consideration in the regression step. Since the ultimate aim of virtual screening is to discover molecules with the highest success rate in the pharmaceutical industry, various aspects of the molecules in different assays were considered by integrating ten different regression models. In conclusion, this paper contributes to pharmaceutical sciences by introducing eleven diverse scaffolds and eight approved drugs that can potentially be used as inhibitors of angiogenesis receptors, including VEGFR, FGFR, and EGFR. Considering three target receptors simultaneously is another central concept and contribution used. This concept could increase the chance of success, while reducing the possibility of resistance to these agents.
Insights
This study identified potential multi-target inhibitors for angiogenesis by screening FDA-approved drugs against vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), and epidermal growth factor receptor (EGFR). The findings offer new therapeutic strategies for cancer treatment.
Area of Science:
- Pharmaceutical Sciences
- Computational Drug Discovery
- Oncology
Background:
- Tumor growth relies on angiogenesis, the formation of new blood vessels.
- Targeting key receptors like VEGFR, FGFR, and EGFR is crucial for inhibiting angiogenesis.
- Developing multi-target inhibitors can enhance efficacy and reduce side effects compared to single-target drugs.
Purpose of the Study:
- To develop a computational methodology for discovering multi-target inhibitors of angiogenesis.
- To screen a library of over 2000 FDA-approved drugs for potential angiogenesis inhibitors.
- To identify novel drug candidates targeting VEGFR, FGFR, and EGFR simultaneously.
Main Methods:
- An ensemble approach combining classification and regression models was employed.
- Deep autoencoder classification models were used for initial screening.
- High-throughput virtual screening integrated ten regression models to assess drug efficacy and safety.
Main Results:
- Eleven diverse molecular scaffolds and eight FDA-approved drugs were identified as potential multi-target inhibitors.
- The identified compounds show promise in inhibiting VEGFR, FGFR, and EGFR.
- The study validated a novel computational approach for drug discovery.
Conclusions:
- This research provides a valuable resource for developing novel anti-angiogenesis therapies.
- Simultaneous targeting of VEGFR, FGFR, and EGFR offers a promising strategy to overcome drug resistance.
- The identified drugs and scaffolds represent potential lead compounds for cancer drug development.
More Related Videos
08:04In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
Published on: May 11, 2021
07:32Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library
Published on: September 30, 2019
Related Concept Videos
Mechanism of Angiogenesis
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Targeted Cancer Therapies
There are several types of targeted therapies against...
Drug Discovery: Overview
Regulation of Angiogenesis and Blood Supply